{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:48:28Z","timestamp":1788961708006,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019573","name":"Amsterdam University Medical Centres","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019573","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jtha.2025.02.022","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T12:10:27Z","timestamp":1741090227000},"page":"2255-2261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment and outcomes after on-treatment recurrent venous thromboembolism in patients with cancer: a post hoc analysis of the Hokusai venous thromboembolism cancer study"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8269-9473","authenticated-orcid":false,"given":"Vincent R.","family":"Lanting","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kika","family":"van Bergen en Henegouwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris T.M.","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelise","family":"Segers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary E.","family":"Raskob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Pieter Willem","family":"Kamphuisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry R.","family":"B\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Verhamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Di Nisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"van Es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.02.022_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1160\/TH15-08-0686","article-title":"Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study","volume":"117","author":"Cohen","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.022_bib2","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ajh.25494","article-title":"Bleeding incidence and risk factors among cancer patients treated with anticoagulation","volume":"94","author":"Angelini","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2025.02.022_bib3","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtha.2025.02.022_bib4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.022_bib5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.02.022_bib6","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2025.02.022_bib7","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.02.022_bib8","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.02.022_bib9","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/jth.12955","article-title":"Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis","volume":"13","author":"Schulman","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.022_bib10","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1538-7836.2009.03326.x","article-title":"Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients","volume":"7","author":"Carrier","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.022_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.thromres.2014.04.028","article-title":"Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis","volume":"134","author":"Ihaddadene","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.02.022_bib12","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtha.2025.02.022_bib13","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.02.022_bib14","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.022_bib15","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.02.022_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.02.022_bib17","first-page":"42","article-title":"Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism","volume":"31","author":"Wilson","year":"2001","journal-title":"Haemostasis"},{"key":"10.1016\/j.jtha.2025.02.022_bib18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1538-7836.2004.01053.x","article-title":"The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients","volume":"3","author":"Al-Yaseen","year":"2005","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625001205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625001205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T07:29:44Z","timestamp":1778138984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625001205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1538783625001205"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.02.022","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment and outcomes after on-treatment recurrent venous thromboembolism in patients with cancer: a post hoc analysis of the Hokusai venous thromboembolism cancer study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}